knowledge -WSS

knowledge

author：hotspot 2025-09-30 01:01:46 - browse：2

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Data don't support strong claims for Covid

Wikipedia

WSS

Congress needs to close a vaccine

Congress needs to close a vaccine

Neurocrine congenital adrenal hyperplasia trial succeeds

An outdated Medicare rule harms dementia patients with anxiety

How the messy conversation about Dolly changed bioethics

Why the quest to eradicate polio has stumbled

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Information blocking fines are now fair game in health care

Novavax promises a turnaround & Lilly roils the obesity market

Free Covid tests will again be offered to all U.S. households

Sports medicine is finally prioritizing gender equality

PBMs drew scrutiny in House hearing — and so did pharma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stopping antidepressants leads to symptoms for 1 in 6 patients

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Transgender sports debate: Physicians say bans are health issue

leisure time

Congress needs to close a vaccine

ASCO Takeaways: Winners, snoozers, and the art of cancer care

White House Covid adviser calls on docs to combat misinformation

The struggle to figure out which patients 'deserve' Wegovy

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Fed up with FDA, ALS advocates consider a take

focus

focus

Wikipedia

knowledge